5-Iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling

Area of Science:

• Molecular Biology
• Cell Biology
• Immunology

Background:

• Receptor-interacting protein kinases (RIPK) are key regulators of cell death pathways.
• IKK1/2 and p38/MAPK-activated protein kinase 2 (MK2) pathways act as checkpoints phosphorylating RIPK1 to inhibit activation.
• Understanding these checkpoints is crucial for controlling cell fate decisions.

Purpose of the Study:

• To investigate TNF-induced cell death mechanisms in MK2-deficient cells.
• To identify novel compounds that modulate RIPK1-mediated cell death.
• To elucidate the role of 5-Iodotubercidin (5-ITu) in necroptosis.

Main Methods:

• Utilized MK2-deficient mouse embryonic fibroblasts (MEFs) and RAW264.7 macrophages.
• Administered TNF-alpha and lipopolysaccharide (LPS) to induce cell death.
• Screened a library of 149 kinase inhibitors, including 5-Iodotubercidin (5-ITu).
• Performed mechanistic studies involving RIPK1 and IKK signaling pathway analysis.

Main Results:

• MK2 deficiency predominantly led to necroptosis, even without caspase inhibitors.
• Inhibiting RIPK3 switched cell death from necroptosis to apoptosis in MK2-deficient cells.
• 5-Iodotubercidin (5-ITu) was identified as a potent sensitizer to TNF-induced necroptosis in MK2-deficient cells.
• 5-ITu enhanced LPS-induced necroptosis in combination with MK2 inhibition.
• Mechanistic studies showed 5-ITu induces RIPK1-dependent necroptosis by suppressing IKK signaling in MK2-deficient cells.

Conclusions:

• MK2 plays a critical role in preventing necroptosis.
• The kinase inhibitor 5-ITu effectively induces RIPK1-dependent necroptosis.
• 5-ITu demonstrates potential as a therapeutic agent for enhancing necroptosis in contexts like cancer therapy or infectious diseases.
• Targeting RIPK1 signaling with inhibitors like 5-ITu warrants further investigation for therapeutic applications.